Should patients with Barrett's oesophagus be kept under surveillance? The case for

Best Practice and Research: Clinical Gastroenterology

Volumn 22, Issue 4, 2008, Pages 721-739

  Armstrong, David ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

adenocarcinoma; Barrett's oesophagus; surveillance

Indexed keywords

ARGON PLASMA COAGULATION; ARTICLE; BARRETT ESOPHAGUS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SURVEILLANCE; EARLY DIAGNOSIS; ENDOSCOPIC SURGERY; ESOPHAGEAL ADENOCARCINOMA; EVIDENCE BASED PRACTICE; GASTROESOPHAGEAL REFLUX; HUMAN; INCIDENCE; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PREDICTION; PUBLISHING; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION;

BARRETT ESOPHAGUS; ENDOSCOPY, GASTROINTESTINAL; HUMANS; MASS SCREENING; POPULATION SURVEILLANCE; REPRODUCIBILITY OF RESULTS;

EID: 47849088766     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2008.03.002     Document Type: Article

References (124)

1. Eloubeidi M.A., Mason A.C., Desmond R.A., et al. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?. Am J Gastroenterol 98 (2003) 1627-1633
2. Fitzgerald R.C. Genetics and prevention of oesophageal adenocarcinoma. Recent Results Cancer Res 166 (2005) 35-46
3. Blot W.J., Devesa S.S., Kneller R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (1991) 1287-1289
4. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2006 56 (2006) 106-130
5. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
6. Anagnostopoulos G.K., Pick B., Cunliffe R., et al. Barrett's esophagus specialist clinic: what difference can it make?. Dis Esoph 19 (2006) 84-87
7. Jankowski J., Harrison R.F., Perry I., et al. Seminar: Barrett's metaplasia. Lancet 356 (2000) 2079-2085
8. Haggitt R.C., Tryzelaar J., Ellis F.H., et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 70 (1978) 1-5
9. Hamilton S.R., and Smith R.R. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 87 (1987) 301-312
10. Hameeteman W., Tytgat G.N., Houthoff H.J., et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96 (1989) 1249-1256
11. Paulson T.G., and Reid B.J. Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell 6 (2004) 11-16
12. Prach A.T., MacDonald T.A., Hopwood D.A., et al. Increasing Barrett's oesophagus: education, enthusiasm or epidemiology?. Lancet 350 (1997) 933
13. Conio M., and Cameron A.J. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmstead county. Gut 48 (2001) 304-309
14. van Soest E.M., Dieleman J.P., Siersema P.D., et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 54 (2005) 1062-1066
15. Post P.N., Siersema P.D., and Van Dekken H. Rising incidence of clinically evident Barrett's oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol 42 (2007) 17-22
16. Pera M., Cameron A.J., Trastek V.F., et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104 (1993) 510-513
17. Blot W.J., DiBisceglia A.M., Kieely R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (1993) 1297-1299
18. Dulai G.S. Surveying the case for surveillance. Gastroenterology 122 (2002) 820-825
19. Provenzale D., Schmitt C., and Wong J.B. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 94 (1999) 2043-2053
20. Inadomi J.M., Sampliner R., Lagergren J., et al. Screening and surveillance for Barrett's esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 138 (2003) 176-186
21. Gerson L.B., Groeneveld P.W., and Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2 (2004) 868-879
22. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129 (2005) 1825-1831
23. Veldhuyzen van Zanten S.J.O., Thomson A.B.R., Barkun A.N., et al. The prevalence of Barrett's oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy. Aliment Pharmacol Ther 23 (2006) 595-599
24. Dulai G.S., Guha S., Kahn K.L., et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 122 (2002) 26-33
25. Dulai G.S., Shekelle P.G., Jensen D.M., et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol 100 (2005) 775-783
26. De Jonge P.J.F., Steyerberg E.W., Kuipers E.J., et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 101 (2006) 1421-1429
27. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
28. Sharma P., McQuaid K., Dent J., et al. AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett's esophagus. Gastroenterology 127 (2004) 310-330
29. Wang K.K., Wongkeesong M., and Buttar N.S. American Gastroenterological Association technical review on the role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 128 (2005) 1471-1505
30. Armstrong D., Marshall J.K., Chiba N., et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol 19 (2005) 15-35
31. Dellon E.S., and Shaheen N.J. Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival?. J Clin Oncol 23 (2005) 4478-4482
32. Spechler S.J., and Barr H. Review article: screening and surveillance of Barrett's oesophagus: what is a cost-effective framework?. Aliment Pharmacol Ther 19 (2004) 49-53
33. Shaheen N.J., Crosby M.A., Bozymski E.M., et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 119 (2000) 333-338
34. Jankowski J., Provenzale D., and Moayyedi P. Oesophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology 122 (2002) 558-590
35. Murray L., Watson P., Johnston B., et al. Risk of adenocarcinoma in Barrett's oesophagus: a population based study. BMJ 327 (2003) 534-535
36. Gladman L., Chapman W., Iqbal T.H., et al. Barrett's oesophagus: an audit of surveillance over a 17-year period. Eur J Gastroenterol Hepatol 18 (2006) 271-276
37. Solaymani-Dodaran M., Logan R.F.A., West J., et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53 (2004) 1070-1074
38. Thomas T., Abrams K.R., de Caestecker J.S., et al. Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 26 (2007) 1465-1477
39. Peters F.T., Ganesh S., Kuipers E.J., et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 45 (1999) 489-494
40. Gore S., Healey C.J., Sutton R., et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 7 (1993) 623-628
41. Cooper B.T., Chapman W., Neumann C.S., et al. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 23 (2006) 727-733
42. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (2003) 47-56
43. Jankowski J., and Moayyedi P. Aspirin as chemoprevention for Barrett's esophagus: a large RCT underway in the UK (extended original research correspondence). J Natl Cancer Inst 96 (2004) 885-887
44. Jankowski J.A., and Hawk E.T. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 101-111
45. El-Serag H.B., Aguirre T.V., Davis S., et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99 (2004) 1884-1886
46. Hillman L.C., Chiragakis L., Shadbolt B., et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 180 (2004) 387-391
47. Jankowski J., and Barr H. Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. Br Med J 332 (2006) 1512 (Letter)
48. Thomas T., and de Caestecker J.S. Surveillance in Barrett's oesophagus. Eur J Gastroenterol Hepatol 18 (2006) 585-588
49. Headrick J.R., Nichols III F.C., Miller D.L., et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 73 (2002) 1697-1702
50. Buttar N.S., Wang K.K., Sebo T.J., et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120 (2001) 1630-1639
51. Dar M.S., Goldblum J.R., Rice T.W., et al. Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?. Gut 52 (2003) 486-489
52. Skacel M., Petras R.E., Gramlich T.L., et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 95 (2000) 3383-3387
53. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 63 (2006) 570-580
54. Miros M., Kerlin P., and Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 32 (1991) 1441-1446
55. O'Connor J.B., Falk G.W., and Richter J.E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 94 (1999) 2037-2042
56. Weston A.P., Badr A.S., and Hassanein R.S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 94 (1999) 3413-3419
57. Reid B.J., Levine D.S., Longton G., et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subset. Am J Gastroenterol 95 (2000) 1669-1676
58. Montgomery E., Goldblum J.R., Greenson J.K., et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32 (2001) 379-388
59. Schnell T.G., Sontag S.J., Chejfec G., et al. Long-term nonsurgical management of Barrett's esophagus with high grade dysplasia. Gastroenterology 120 (2001) 1607-1619
60. Conio M., Blanchi S., Lapertosa G., et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma. A prospective study. Am J Gastroenterol 98 (2003) 1931-1939
61. Lim C.H., Treanor D., Dixon M.F., et al. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy 39 (2007) 581-587
62. Rudolph R.E., Vaughan T.L., Storer B.E., et al. Effect of segment length on risk for neoplastic progression in patients with Barrett's esophagus. Ann Intern Med 132 (2000) 612-620
63. Gopal D.V., Lieberman D.O., Magaret N., et al. Risk factors for dysplasia in patients with Barrett's esophagus. Results from a multicenter consortium. Dig Dis Sci 48 (2003) 1537-1541
64. Weston A.P., Sharma P., Mathur S., et al. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol 99 (2004) 1657-1666
65. Bani-Hani K.E., Bani-Hani B.K., and Martin I.G. Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma. World J Gastroenterol 11 (2005) 6807-6814
66. Shaheen N.J., Green B., Medapalli R.K., et al. The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program. Gastroenterology 129 (2005) 429-436
67. Kruijshaar M.E., Siersema P.D., Janssens C.J.W., et al. Essink-Bot MLE for the CYBAR Study Group. Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low. Gastrointest Endosc 65 (2007) 26-30
68. Gerson L.B., Ullah N., Hastie T., et al. Does cancer risk affect health-related quality of life in patients with Barrett's esophagus?. Gastrointest Endosc 65 (2007) 16-25
69. Rimer B.K., Briss P.A., Zeller P.K., et al. Informed decision making: what is its role in cancer screening?. Cancer 101 (2004) 1214-1228
70. Essink-Bot M.L., Kruijshaar M.E., Bac D.J., et al. Different perceptions of the burden of upper GI endoscopy: an empirical study in three patient groups. Qual Life Res 16 (2007) 1309-1318
71. Kruijshaar M.E., Kerkhof M., Siersema P.D., et al. Essink-Bot ML for the CYBAR Study Group. The burden of upper gastrointestinal endoscopy in patients with Barrett's esophagus. Endoscopy 38 (2006) 873-878
72. Eliakim R., Sharma V.K., Yassin K., et al. A prospective study of the diagnostic accuracy of PillCam esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol 39 (2005) 572-578
73. Saeian K., Staff D.M., Vasilopoulos S., et al. Unsedated transnasal endoscopy accurately detects Barrett's esophagus and dysplasia. Gastrointest Endosc 56 (2002) 472-478
74. Lin O.S., Schembre D.B., Mergener K., et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett's esophagus in patients with chronic gastroesophageal reflux. Gastrointest Endosc 65 (2007) 577-583
75. MacDonald C.E., Wicks A.C., and Playford R.J. Final results from 10-year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 321 (2000) 1252-1255
76. Van der Burgh A., Dees J., Hop W.C.J., et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 39 (1996) 5-8
77. McGarrity T. Barrett's oesophagus. The continuing conundrum. BMJ 321 (2000) 1238-1239
78. Fountoulakis A., Zafirellis K.D., and Dolan K. Effect of surveillance for Barrett's oesophagus on oesophageal cancer. Br J Surg 91 (2004) 997-1003
79. Corley D.A., Levine T.R., Habel L.A., et al. Surveillance and survival in Barrett's adenocarcinomas: a population based study. Gastroenterology 122 (2002) 633-640
80. Wright T.A., Gray M.R., Morris A.I., et al. Cost effectiveness of detecting Barrett's cancer. Gut 39 (1996) 574-579
81. Eisen G.M., Lieberman D.A., Fennerty M.B., et al. Screening and surveillance in Barrett's esophagus. A call to action. Clin Gastroenterol Hepatol 2 (2004) 861-864
82. Perdue D.G., Murray J., and Wang K.K. The wizards of odds: cost effectiveness model, Barrett's screening and surveillance guidelines. Clin Gastroenterol Hepatol 2 (2004) 865-867
83. Soni A., Sampliner R.E., and Sonnenberg A. Screening for high grade dysplasia in gastro-esophageal reflux disease: is it cost effective?. Am J Gastroenterol 95 (2000) 2086-2093
84. Sonnenberg A., Soni A., and Sampliner R.E. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther 16 (2002) 41-54
85. Watson A., Heading R.C., and Shepherd N.A. British Society of Gastroenterology, Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. August 2005. Available at:. http://www.bsg.org.uk Accessed January 26, 2007
86. Barr H., Kendall C., Bazant-Hegemark F., et al. Endoscopic screening and surveillance for Barrett's esophagus - clinical implications. Med Gen Med 8 (2006) 88
87. Peters J.H., Clark G.W.B., Ireland A.P., et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and non-surveyed patients. J Thorac Cardiovasc Surg 108 (1994) 813-822
88. Sandwick J.W., van Lanschot J.J.B., Kuiken B.W., et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 43 (1998) 216-222
89. Streitz J.M., Andrews C.W., and Ellis F.H. Endoscopic surveillance of Barrett's esophagus: does it help?. J Thorac Cardiovasc Surg 105 (1993) 383-388
90. Van Sandick J.W., van Lanschot J.J.B., Kuiken B.W., et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 43 (1998) 212-222
91. Fitzgerald R.C., Saeed I.T., Khoo D., et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 46 (2001) 1892-1898
92. Bani Hani K., Sue-Ling H., Johnson D., et al. Barrett's oesophagus: results from a 13 year surveillance programme. Eur J Gastroenterol Hepatol 12 (2000) 649-654
93. Cooper G.S., Yuan Z., Chak A., et al. Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer 95 (2002) 32-38
94. Kearney D.J., Crump C., Maynard C., et al. A case-control study of endoscopy and mortality from adenocarcinoma of the esophagus or gastric cardia in persons with GERD. Gastrointest Endosc 57 (2003) 823-829
95. Bampton P.A., Schloithe A., Bull J., et al. Improving surveillance for Barrett's oesophagus. Br Med J 332 (2006) 1320-1323
96. Armstrong D. Towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia. Aliment Pharmacol Ther 20 Suppl 5 (2004) 40-47
97. Sharma P., Dent J., Armstrong D., et al. The development and validation of an endoscopic grading system for Barrett's esophagus - the Prague C and M criteria. Gastroenterology 131 (2006) 1392-1399
98. Mandal A., Playford R.J., and Wicks A.C. Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. Aliment Pharmacol Ther 17 (2003) 1319-1324
99. Amamra N., Touzet S., Colin C., et al. Current practice compared with the international guidelines: endoscopic surveillance of Barrett's esophagus. J Eval Clin Pract 13 (2007) 789-794
100. Vakil N., van Zanten S.V., Kahrilas P., et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101 (2006) 1900-1920
101. MacNeil-Covin L., Casson A.G., Malatjalian D., et al. A survey of Canadian gastroenterologists about the management of Barrett's esophagus. Can J Gastroenterol 17 (2003) 313-317
102. van Sandick J.W., Bartelsman J.F.W., van Lanschot J.J.B., et al. Surveillance of Barrett's esophagus: physicians' practices and review of current guidelines. Eur J Gastroenterol Hepatol 12 (2000) 111-117
103. Cruz-Correa M., Gross C.P., Canto M.I., et al. The impact of practice guidelines in the management of Barrett esophagus: a national prospective cohort study of physicians. Arch Int Med 161 (2001) 2588-2595
104. Smith A.M., Maxwell-Armstrong C.A., Welch N.T., et al. Surveillance for Barrett's oesophagus in the UK. Br J Surg 86 (1999) 276-280
105. Heitmiller R.F., Redmond M., and Hamilton S.R. Barrett's esophagus with high-grade dysplasia: an indication for prophylactic esophagectomy. Ann Surg 224 (1996) 66-71
106. Zanninotto G., Parenti A.R., Ruol A., et al. Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br J Surg 87 (2000) 1102-1105
107. Anderson M.R., and Jankowski J.A. The treatment, management and prevention of oesophageal cancer. Expert Opin Biol Ther 1 (2001) 1017-1028
108. Ell C., May A., Gossner L., et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 118 (2000) 670-677
109. May A., Gossner L., Pech O., et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and long-term results of a new treatment approach. Eur J Gastroenterol Hepatol 14 (2002) 1085-1091
110. Panjehpour M., Overholt B.F., Haydek J.M., et al. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol 95 (2000) 2177-2184
111. Overholt B.F., Lightdale C.J., Wang K.K., et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62 (2005) 488-498
112. Attwood S.E., Lewis C.J., Caplin S., et al. Argon beam coagulation as therapy for high-grade dysplasia in Barrett's oesophagus. Clin Gastroenterol Hepatol 1 (2003) 258-263
113. Kelty C.J., Ackroyd R., Brown N.J., et al. Endoscopic ablation of Barrett's oesophagus: a randomized, controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 20 (2004) 1289-1296
114. Sampliner R.E. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 97 (2002) 1888-1995
115. Hillman L.C., Chiragakis L., Clarke A.C., et al. Barrett's esophagus: macroscopic markers and the prediction of dysplasia and adenocarcinoma. J Gastroenterol Hepatol 18 (2003) 526-533
116. Ell C., May E., Pech O., et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 65 (2007) 3-10
117. Barr H. Barrett's esophagus: treatment with 5-aminolevulinic acid photodynamic therapy. Gastrointest Endosc Clin N Am 10 (2000) 421-437
118. Hage M., Siersema P.D., van Dekken H., et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomized trial. Gut 53 (2004) 785-790
119. Dellon E.S., and Shaheen N.J. Barrett's esophagus and the costs of "doing something". Gastrointest Endosc 65 (2007) 31-35
120. Ramnath G., and Bampton P.A. Surveillance for Barrett's oesophagus-if you are going to do it, do it properly. Med J Aust 180 (2004) 139-140
121. Harrison R., Perry I., Haddadin W., et al. Detection of intestinal metaplasia in Barrett's esophagus: An observational study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 102 (2007) 1154-1161
122. Craanen M.E., Blok P., Meijer G.A., et al. Surveillance in Barrett's oesophagus: a critical reappraisal. Scand J Gastroenterol 37 Suppl 236 (2002) 4-8
123. Spechler S.J. Managing Barrett's esophagus. Brit Med J 326 (2003) 892-894
124. Spechler S.J. Screening and surveillance for Barrett's esophagus-an unresolved dilemma. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 470-471